Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Utah Medical Products (UTMD) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to 22.98%.

  • Utah Medical Products' EBITDA Margin fell 269400.0% to 22.98% in Q3 2025 from the same period last year, while for Sep 2025 it was 30.48%, marking a year-over-year decrease of 89200.0%. This contributed to the annual value of 30.87% for FY2024, which is 50100.0% down from last year.
  • As of Q3 2025, Utah Medical Products' EBITDA Margin stood at 22.98%, which was down 269400.0% from 48.99% recorded in Q2 2025.
  • In the past 5 years, Utah Medical Products' EBITDA Margin registered a high of 51.17% during Q4 2022, and its lowest value of 9.65% during Q4 2024.
  • In the last 5 years, Utah Medical Products' EBITDA Margin had a median value of 29.32% in 2024 and averaged 31.18%.
  • Data for Utah Medical Products' EBITDA Margin shows a peak YoY increase of 265500bps (in 2024) and a maximum YoY decrease of -359600bps (in 2024) over the last 5 years.
  • Utah Medical Products' EBITDA Margin (Quarter) stood at 32.1% in 2021, then surged by 59bps to 51.17% in 2022, then dropped by -11bps to 45.62% in 2023, then tumbled by -79bps to 9.65% in 2024, then surged by 138bps to 22.98% in 2025.
  • Its EBITDA Margin was 22.98% in Q3 2025, compared to 48.99% in Q2 2025 and 38.71% in Q1 2025.